ArticleWorld journal of surgical oncology2026
Exploratory analysis of serial pan-immune-inflammation value and its early dynamics during neoadjuvant chemotherapy as a predictor of complete cytoreduction at interval debulking surgery in advanced ovarian cancer: a retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundComplete cytoreduction at interval debulking surgery (IDS) is the most critical prognostic determinant for advanced ovarian cancer patients receiving neoadjuvant chemotherapy (NACT), yet accurate preoperative prediction remains challenging. Pan-immune-inflammation value (PIV) has emerged as a superior predictor in multiple malignancies compared to simple inflammatory ratios, yet its predictive value for surgical outcomes after NACT in ovarian cancer remains uninvestigated. This study aimed to explore the predictive value of PIV at multiple timepoints and its early dynamics during NACT for complete cytoreduction at IDS in patients with advanced ovarian cancer.
methodsPIV was calculated at three timepoints in 231 enrolled patients: before NACT (PIV-0), after one cycle of NACT (PIV-1), and before IDS (PIV-2). Early PIV difference was defined as the percentage change between PIV-0 and PIV-1. Receiver operating characteristic analysis and logistic regression were performed to assess the predictive value for cytoreduction status. Associations with chemotherapy response indicators and survival outcomes were also evaluated.
resultsPatients with incomplete cytoreduction had significantly higher PIV levels at all timepoints and less favorable early PIV dynamics (all P < 0.001). The area under the curve for PIV-0, PIV-1, PIV-2, and early PIV difference were 0.762, 0.850, 0.754, and 0.787, with optimal cut-off values of 660.6, 404.9, 219.4, and − 19.4%, respectively. Multivariate analysis identified elevated PIV-0 (OR = 4.06), PIV-1 (OR = 5.31), and unfavorable early PIV difference (OR = 9.93) as independent predictors, while PIV-2 lost significance. High PIV levels at all timepoints and unfavorable early dynamics were associated with lower KELIM score, higher intraoperative peritoneal cancer index, lower chemotherapy response score, and worse survival.
conclusionsPIV and its early dynamics during NACT are potential predictive biomarkers for surgical outcomes in advanced ovarian cancer. Early PIV assessments may help identify patients at risk of incomplete cytoreduction and guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.